| Literature DB >> 22567320 |
Michael Saulle1, Brian D Greenwald.
Abstract
Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disease that is a long-term consequence of single or repetitive closed head injuries for which there is no treatment and no definitive pre-mortem diagnosis. It has been closely tied to athletes who participate in contact sports like boxing, American football, soccer, professional wrestling and hockey. Risk factors include head trauma, presence of ApoE3 or ApoE4 allele, military service, and old age. It is histologically identified by the presence of tau-immunoreactive NFTs and NTs with some cases having a TDP-43 proteinopathy or beta-amyloid plaques. It has an insidious clinical presentation that begins with cognitive and emotional disturbances and can progress to Parkinsonian symptoms. The exact mechanism for CTE has not been precisely defined however, research suggest it is due to an ongoing metabolic and immunologic cascade called immunoexcitiotoxicity. Prevention and education are currently the most compelling way to combat CTE and will be an emphasis of both physicians and athletes. Further research is needed to aid in pre-mortem diagnosis, therapies, and support for individuals and their families living with CTE.Entities:
Year: 2012 PMID: 22567320 PMCID: PMC3337491 DOI: 10.1155/2012/816069
Source DB: PubMed Journal: Rehabil Res Pract ISSN: 2090-2867
Risk factors associated with chronic traumatic encephalopathy.
| (i) Head trauma: single or repetitive | |
| (ii) History of head concussion | |
| (iii) Participation in the following | |
| Boxing | |
| American football: offensive/defensive | |
| Soccer | |
| Professional wrestling | |
| Hockey | |
| Military service: blast injuries | |
| (iv) Length of sport participation | |
| (v) Epileptics | |
| (vi) Victims of domestic abuse | |
| (vii) Age of injuries: younger ages and older ages | |
| (viii) Genetic variation: ApoE3 or ApoE4 |
Areas of damage in the brain.
|
| |
| (i) Reduced brain weight with atrophy of | |
| Frontal lobe | |
| Temporal lobe | |
| Parietal lobe | |
| Occipital lobe | |
| (ii) Enlargement of lateral and third ventricles | |
| (iii) Thinning of the corpus callosum | |
| (iv) Cavum septum pellucidum with fenestrations | |
| (v) Scarring and neuronal loss of cerebellar tonsils | |
| (vi) Pallor of substantia nigra | |
|
| |
|
| |
| (i) Superficial cortical layers | |
| (ii) Dorsolateral frontal | |
| (iii) Subcallosal | |
| (iv) Insular | |
| (v) Temporal | |
| (vi) Dorsolateral parietal | |
| (vii) Inferior occipital cortices | |
| (viii) Thalamus | |
| (ix) Hypothalamus | |
| (x) Substantia nigra | |
| (xi) Olfactory bulbs | |
| (xii) Hippocampus | |
| (xiii) Entorhinal cortex | |
| (xiv) Amygdala | |
| (xv) Brainstem | |
Emerging histomorphologic phenotypes in American athletes.
| Phenotype | Histological findings |
|---|---|
| 1 | Sparse to frequent NFT and NTs in the cerebral cortex and brainstem without involvement of the subcortical nuclei, basal ganglia, or cerebellum without any beta-amyloid |
| 2 | Sparse to frequent NFT and NTs in the cerebral cortex and brainstem with diffuse beta-amyloid deposition. No involvement of the subcortical nuclei, basal ganglia, or cerebellum |
| 3 | Higher concentrations of NFTs and NTs only in the brainstem. No involvement elsewhere or any beta-amyloid |
| 4 | Sparse NFTs and NTs in the cerebral cortex, brainstem, subcortical nuclei, and basal ganglia with an unaffected cerebellum and no beta-amyloid [ |
Clinicopathological correlations [5].
| Damage area | Clinical presentation |
|---|---|
| Hippocampus | Early deficits in memory |
|
| |
| Frontal cortex and underlying | Dysexecutive symptoms |
|
| |
| Dorsolateral parietal | Visuospatial difficulties |
|
| |
| Substantia nigra | Parkinsonian motor features |
|
| |
| Cortical and subcortical frontal damage | Gait disorder: staggered, slowed, ataxic |
|
| |
| Brainstem nuclei | Dysarthria, dysphagia, |
|
| |
| Amygdala | Aggression and violent outbursts |